Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 in moderate-to-severe plaque psoriasis (phase IIb, China)
CTR20190534Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebdarokimab in plaque psoriasis, psoriatic arthritis (PsA), nail psoriasis, sponsored by Akeso, Inc.. Started Nov 2019; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)nail psoriasis
Beyond the preview
Go deeper on CTR20190534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190534.